Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer
Objective:To compare the efficacy and safety of pemetrexed-based with paclitaxel-based chemotherapy as third-line treatment for patients with advanced breast cancer. Methods: Between January 2009 and February 2016, 109 patients pathologically confirmed with advanced breast cancer in Jiangsu Cancer H...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Third Party Medicine International Publishing Group Co. Limited
2017-06-01
|
Series: | Journal of International Translational Medicine |
Subjects: | |
Online Access: | http://www.jitm.hk/EN/abstract/abstract242.shtml |
id |
doaj-b9f3484cb76e477d9221689135c8c784 |
---|---|
record_format |
Article |
spelling |
doaj-b9f3484cb76e477d9221689135c8c7842020-11-25T00:36:54ZengThird Party Medicine International Publishing Group Co. Limited Journal of International Translational Medicine 2227-63942017-06-0152636610.11910/2227-6394.2017.05.02.02JITM2017050202Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast CancerTing QIAN0Xin-en HUANG1Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, 210000, ChinaDepartment of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, 210000, ChinaObjective:To compare the efficacy and safety of pemetrexed-based with paclitaxel-based chemotherapy as third-line treatment for patients with advanced breast cancer. Methods: Between January 2009 and February 2016, 109 patients pathologically confirmed with advanced breast cancer in Jiangsu Cancer Hospital and Institute of Cancer Research were enrolled, and divided into group A (treated with pemetrexed-based regimen as third-line chemotherapy) and group B (treated with paclitaxel-based regimen as third-line chemotherapy). Other combined chemotherapeutic agents included lobaplatin (or carboplatin) and epirubicin. Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate tumor responses.Results: Comparison between group A (52 patients) and group B (57 patients) suggested that the total response rate (19.2% vs. 21.1%) and disease control rate (40.4% vs. 35.1%) were not statistically different (P>0.05). The incidence of adverse reactions such as leukopenia, thrombocytopenia, anemia, vomiting, increased alanine transaminase, and rash in group A was significantly fewer than that in group B (P<0.05).Conclusion: Pemetrexed-based chemotherapy is as effective as paclitaxel-based chemotherapy in treating patients with advanced breast cancer, with acceptable adverse events.http://www.jitm.hk/EN/abstract/abstract242.shtmlBreast cancerPemetrexedPaclitaxelChemotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ting QIAN Xin-en HUANG |
spellingShingle |
Ting QIAN Xin-en HUANG Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer Journal of International Translational Medicine Breast cancer Pemetrexed Paclitaxel Chemotherapy |
author_facet |
Ting QIAN Xin-en HUANG |
author_sort |
Ting QIAN |
title |
Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer |
title_short |
Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer |
title_full |
Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer |
title_fullStr |
Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer |
title_full_unstemmed |
Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer |
title_sort |
comparison of the efficacy and safety of pemetrexed-based versus paclitaxel-based chemotherapy as third-line treatment for patients with advanced breast cancer |
publisher |
Third Party Medicine International Publishing Group Co. Limited |
series |
Journal of International Translational Medicine |
issn |
2227-6394 |
publishDate |
2017-06-01 |
description |
Objective:To compare the efficacy and safety of pemetrexed-based with paclitaxel-based chemotherapy as third-line treatment for patients with advanced breast cancer. Methods: Between January 2009 and February 2016, 109 patients pathologically confirmed with advanced breast cancer in Jiangsu Cancer Hospital and Institute of Cancer Research were enrolled, and divided into group A (treated with pemetrexed-based regimen as third-line chemotherapy) and group B (treated with paclitaxel-based regimen as third-line chemotherapy). Other combined chemotherapeutic agents included lobaplatin (or carboplatin) and epirubicin. Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate tumor responses.Results: Comparison between group A (52 patients) and group B (57 patients) suggested that the total response rate (19.2% vs. 21.1%) and disease control rate (40.4% vs. 35.1%) were not statistically different (P>0.05). The incidence of adverse reactions such as leukopenia, thrombocytopenia, anemia, vomiting, increased alanine transaminase, and rash in group A was significantly fewer than that in group B (P<0.05).Conclusion: Pemetrexed-based chemotherapy is as effective as paclitaxel-based chemotherapy in treating patients with advanced breast cancer, with acceptable adverse events. |
topic |
Breast cancer Pemetrexed Paclitaxel Chemotherapy |
url |
http://www.jitm.hk/EN/abstract/abstract242.shtml |
work_keys_str_mv |
AT tingqian comparisonoftheefficacyandsafetyofpemetrexedbasedversuspaclitaxelbasedchemotherapyasthirdlinetreatmentforpatientswithadvancedbreastcancer AT xinenhuang comparisonoftheefficacyandsafetyofpemetrexedbasedversuspaclitaxelbasedchemotherapyasthirdlinetreatmentforpatientswithadvancedbreastcancer |
_version_ |
1725303699775946752 |